Revivo BioSystems’s organ-on-a-chip system simulates the interaction of human skin with the substance being tested.
German specialty chemicals company Evonik has invested in Singapore start-up Revivo BioSystems, which provides an alternative to animal testing.
The investment – which is Evonik’s first direct investment in the city-state – will support the development and commercialisation of a technology that uses a realistic 4D model of human skin for the testing of chemical, cosmetic and pharmaceutical compounds.
